Nabumetone has been approved in the United States

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Nabumetone studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
BRL14777/262 III An open-label study assessing the population pharmacokinetics, safety and efficacy of nabumetone in patients with juvenile rheumatoid arthritis (JRA) requiring NSAID therapy.
BRL-14777/267 III A Randomized, Double-Blind, Placebo-Controlled, Endoscopic Study to Assess the Gastroduodenal Effects of an Investigational Formulation of Nabumetone, Relafen, Naproxen Sodium, and Placebo Administered to Healthy Subjects.
269 I An evaluation of the COX-1 and COX-2 inhibitory activity of four potential clinical doses of nabumatone (NAB) Q, relative to repeat doses of naproxen sodium 550mg, rofecoxib 50mg, and Relafen® 2000mg.
BRL-014777/268 I A Single Dose Study to Evaluate the Dose Proportionality of the Tablet Formulation of Nabumetone Q and the Relative Bioavailability of Nabumetone Q Compared to RELAFEN in Healthy Subjects
BRL-14777/275 I A Study to Determine the Steady State Pharmacokinetics of Total and Unbound 6-Methoxy-2-Napthylacetic Acid (6-MNA) After Repeat Doses of the Tablet Formulation of Nabumetone Q and Commercial Relafen (1000 mg and 2000 mg each UID) in Healthy Subjects.